Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0240066 (
iron deficiency
)
7,156
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Alopecia in women is a common problem, and conflicting observational data have failed to determine whether an association exists between alopecia and
iron deficiency
in women. We therefore utilized an analytical cross-sectional methodology to evaluate whether common types of alopecia in women are associated with decreased tissue iron stores, as measured by serum ferritin. We studied patients with telogen effluvium (n = 30), androgenetic alopecia (n = 52),
alopecia areata
(n = 17), and
alopecia areata
totalis/universalis (n = 7). The normal group consisted of 11 subjects without hair loss from the same referral base and source population as those patients with alopecia. We analyzed the data utilizing the unpaired Student's t test assuming unequal variances with an alpha adjustment for multiple comparisons to assess whether the mean ages, ferritin levels, and hemoglobin levels of women without hair loss differed from the means in each alopecia group. The mean age of patients and normals did not differ significantly. We found that the mean ferritin level (ng per ml [95% confidence intervals]) in patients with androgenetic alopecia (37.3 128.4, 46.1]) and
alopecia areata
(24.9 [17.2, 32.6]) were statistically significantly lower than in normals without hair loss (59.5 [40.8, 78.1]). The mean ferritin levels in patients with telogen effluvium (50.1 [33.9, 66.33]) and
alopecia areata
totalis/universalis (52.3 [23.1, 81.5]) were not significantly lower than in normals. Our findings have implications regarding therapeutics, clinical trial design, and understanding the triggers for alopecia.
...
PMID:Decreased serum ferritin is associated with alopecia in women. 1470 88
Androgenetic alopecia,
alopecia areata
, and telogen effluvium are the primary nonscarring alopecias found in clinical practice. Androgenetic alopecia is considered to be the most common form of human alopecia and is postulated to affect more than 50% of men by age 50.
Alopecia areata
affects up to 2% of the U.S. population. Telogen effluvium frequently occurs after major life events, such as a severe illness, childbirth, or high fever, and may be associated with the use of certain medications or
iron deficiency
, particularly in women. The focus of this review is on the medical treatment of these common hair loss conditions.
...
PMID:Medical treatment of noncicatricial alopecia. 1661 3
Iron deficiency
is the world's most common nutritional deficiency and is associated with developmental delay, impaired behavior, diminished intellectual performance, and decreased resistance to infection. In premenopausal women, the most common causes of iron deficiency anemia are menstrual blood loss and pregnancy. In men and postmenopausal women, the most common causes of iron deficiency anemia are gastrointestinal blood loss and malabsorption. Hemoglobin concentration can be used to screen for
iron deficiency
, whereas serum ferritin concentration can be used to confirm
iron deficiency
. However, the serum ferritin concentration may be elevated in patients with infectious, inflammatory, and neoplastic conditions. Other tests may be needed, such as erythrocyte zinc protoporphyrin concentration, transferrin concentration, serum iron concentration, and transferrin saturation. The cause of
iron deficiency
must be identified. If the patient is male, postmenopausal female, or has risk factors for blood loss, then the patient should be evaluated for sources of blood loss, especially gastrointestinal (eg, colon cancer). Several studies have examined the relationship between
iron deficiency
and hair loss. Almost all have addressed women exclusively and have focused on noncicatricial hair loss. Some suggest that
iron deficiency
may be related to
alopecia areata
, androgenetic alopecia, telogen effluvium, and diffuse hair loss, while others do not. Currently, there is insufficient evidence to recommend universal screening for
iron deficiency
in patients with hair loss. In addition, there is insufficient evidence to recommend giving iron supplementation therapy to patients with hair loss and
iron deficiency
in the absence of iron deficiency anemia. The decision to do either should be based on clinical judgment. It is our practice at the Cleveland Clinic Foundation to screen male and female patients with both cicatricial and noncicatricial hair loss for
iron deficiency
. Although this practice is not evidence based per se, we believe that treatment for hair loss is enhanced when
iron deficiency
, with or without anemia, is treated. Iron deficiency anemia should be treated. Treating
iron deficiency
without anemia is controversial. Treatment of nutritional iron deficiency anemia includes adequate dietary intake and oral iron supplementation. Excessive iron supplementation can cause iron overload and should be avoided, especially in high-risk patients such as those with hereditary hemochromatosis. Patients who do not respond to iron replacement therapy should undergo additional testing to identify other underlying causes of iron deficiency anemia.
...
PMID:The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. 1731 91
Although immunologic processes and hereditary factors are suggested to play an important role in
alopecia areata
, the specific etiology is unclear.
Iron deficiency
has been suggested to play a role, but its effect is controversial. In our case control study, we found a higher mean level of serum iron and ferritin and a lower mean level of TIBC in patients compared to control subjects, but the differences did not reach significance.
...
PMID:Evaluation of serum iron and ferritin levels in alopecia areata. 1862 22